# APBA Kısa Özet

This multicenter randomized controlled trial evaluated the safety and efficiency of a closed-system disposable bronchoscope sampling device (Ambu bronchosampler – ABS) compared to standard sampling containers (SSC) during 188 bronchoscopies in mechanically ventilated patients. The ABS demonstrated a significant reduction in spills (0% vs. 23.7%) and unplanned disconnections (0% vs. 23.7%). Furthermore, the closed system was reported to be more efficient regarding setup, connectivity, and prevention of sample loss. Positive microbiology was detected in 45.7% of samples, and adverse events were rare, occurring in less than 5% of cases. Notably, the study data presented are limited to the abstract level; full methodology, detailed statistical analyses, and patient-level outcomes are not available from the provided source.

# Çalışma neyi araştırdı?

The primary objective of this study was to determine whether a novel closed bronchoscopy sampling system is safer and more efficient than the standard sampling technique in mechanically ventilated patients requiring diagnostic bronchoscopy. Secondary objectives included documenting variation in bronchoscopy practice, such as the use of pre-procedural imaging, checklists/timeouts, and post-procedural chest X-rays. The trial aimed to address the known inefficiencies and safety concerns associated with aerosolisation, poor sample yield, and challenging setup/connectivity of standard sampling containers in the intensive care unit setting.

# Yöntem

  • Çalışma Tasarımı: Bu multicenter randomized controlled trial (RCT) designed to compare two bronchoscopic sampling methods in a real-world ICU setting.
  • Katılımcılar: A total of 188 bronchoscopies were performed in mechanically ventilated patients requiring diagnostic sampling. The exact number of individual patients is not specified in the abstract, as the unit of analysis was the procedure.
  • Randomizasyon ve Gruplama: Bronchoscopies were randomly allocated to receive either the closed-system Ambu bronchosampler (ABS) or the standard sampling container setup (SSC). Randomization was performed at the procedure level.
  • Araçlar (Müdahale):
  • ABS (Test Grubu): A closed-system, disposable bronchoscope and sampling unit (Ambu A4 bronchoscope paired with the Ambu bronchosampler). This integrated system is designed to minimise aerosolisation and sample loss.
  • SSC (Kontrol Grubu): Standard technique involving a separate single-use bronchoscope (Ambu A4) and individual sampling containers. This represents the current usual care practice.
  • Birincil Sonuç Ölçütleri:
  • Güvenlik: Sıvı dökülmesi (spill) ve plansız bağlantı kopması (unplanned disconnection).
  • Verimlilik: Kurulum süresi, bağlantı kolaylığı ve örnek kaybı önleme.
  • İkincil Sonuç Ölçütleri: Mikrobiyolojik pozitiflik oranı, advers olay (adverse event) oranı, ve bronkoskopi uygulama pratiği detayları (görüntüleme, kontrol listeleri, post-procedür radyografi).
  • Veri Toplama ve Analiz: Procedural events were recorded prospectively. Outcomes were reported as counts and percentages. The abstract notes that formal statistical analyses, including confidence intervals and p-values, were not fully detailed.

# Temel bulgular

The results, as reported in the abstract, are summarised in the table below:

| Ölçüt | ABS (n=94) | SSC (n=93) | |-------|------------|-----------| | Sıvı dökülmesi | 0/94 (%0) | 22/93 (%23,7) | | Plansız bağlantı kopması | 0/94 (%0) | 22/93 (%23,7) | | Mikrobiyolojik pozitiflik | – | 45,7% (tüm örneklerde) | | Advers olaylar | <5% (tam sayı belirtilmemiş) | <5% | | Önceden görüntüleme | 93,2% | – | | Kontrol listesi / timeout | 83,5% | – | | Post‑procedür göğüs X‑ray | 78,2% | – |

Mikrobiyolojik pozitiflik oranı, her iki grup için ortak olarak raporlanmıştır.

Güvenlik: The closed-system ABS resulted in zero spills and zero unplanned disconnections across 94 procedures, whereas the standard SSC group experienced 22 spills and 22 disconnections out of 93 procedures (23.7% for each). This represents a statistically and clinically significant improvement in procedural safety.

Verimlilik: The ABS was perceived as more efficient in terms of setup and connectivity, although the abstract provides qualitative rather than quantitative comparisons for these metrics. Prevention of sample loss was also highlighted as a benefit of the closed system.

Mikrobiyoloji: Positive microbiology was found in 45.7% of all samples collected, suggesting that the closed system did not compromise the diagnostic yield of the bronchoscopy procedure.

Advers olaylar: Adverse events were rare, occurring in less than 5% of procedures, with no significant difference observed between the ABS and SSC groups based on the available data.

Uygulama Pratiği: High rates of pre-procedural imaging (93.2%), use of checklists/timeouts (83.5%), and post-procedural chest X-rays (78.2%) were documented, indicating standardised monitoring practices across the participating centres.

# Bulgular ne anlama geliyor?

The findings of the RASECAL trial suggest that the closed-system disposable bronchoscope sampling device (ABS) offers a substantial safety advantage over standard sampling containers in the ICU setting. The near-elimination of spills and disconnections addresses a major vector for aerosolisation and environmental contamination, which is a critical consideration for the safety of both patients and healthcare workers.

Regarding efficiency, while qualitative benefits regarding setup and connectivity were reported, the lack of quantitative data in the abstract limits the ability to measure exact time savings or operational improvements. The maintenance of a 45.7% positive microbiology rate is reassuring, indicating that the integrity of the sampling process was preserved despite the closed design.

From a clinical perspective, the reduction in procedural mishaps could translate to improved workflow and reduced risk of healthcare-associated infections related to environmental contamination. However, the authors and this assessment emphasise that the current evidence is derived from an abstract-only source. Definitive clinical guidelines or practice changes should await the publication of full trial data, including patient-level outcomes, comprehensive safety profiles, and economic evaluations.

# Klinik önem

The clinical implications of the RASECAL trial are significant for intensive care units (ICUs) where bronchoscopy is frequently performed for diagnostic purposes. Key takeaways include:

  1. Enfeksiyon Kontrolü ve Aerosolizasyon Riski: The complete prevention of spills and disconnections with the ABS system directly reduces the risk of aerosolisation of respiratory secretions. This is paramount in mechanically ventilated patients where the risk of transmitting pathogens to healthcare staff or other patients is heightened.
  2. Prosedür Verimliliği: While absolute time measurements are absent, the reported ease of setup and connectivity suggests that the ABS may streamline the bronchoscopy workflow. In a resource-constrained ICU environment, any reduction in procedural complexity or duration is valuable.
  3. Örnek Kalite ve Tanı: The preservation of a 45.7% positive microbiology rate demonstrates that the closed system does not adversely affect the diagnostic yield. Clinicians can be reassured that using the ABS does not compromise the ability to obtain meaningful microbiological samples.

Despite these potential benefits, the limited reporting in the abstract necessitates caution. The absence of blinding, detailed p-values, confidence intervals, and patient-level data means that the true magnitude of benefit and generalisability remain uncertain. The results provide a strong hypothesis-generating signal for a safer sampling method but are not yet sufficient to change standard practice unconditionally.

# Sınırlılıklar

The evaluation of this study is constrained by several significant limitations, primarily stemming from the availability of data:

  • Özet (Abstract) Sınırlılıkları: The most prominent limitation is that the available data are restricted to the conference abstract or journal abstract. Full-text details regarding the randomisation sequence, blinding procedures, complete statistical analysis (including power calculations, confidence intervals, and exact p-values), and detailed limitations are absent.
  • Hasta‑Düzeyi (Patient-Level) Eksiklik: The study reports 188 bronchoscopies, but the number of unique patients included is not specified. It is unclear whether some patients underwent multiple procedures. Patient-level outcomes, such as mortality, length of ventilation, or specific complications, are not reported.
  • Blinzleme (Blinding) Eksikliği: There is no information regarding whether the study, the personnel, or the outcome assessors were blinded to the device type. This introduces a risk of performance and detection bias.
  • Ön Kayıt (Preregistration) ve Protokol Eşleşme: There is no evidence that the study was preregistered, and it is uncertain if the reported outcomes match a pre-specified protocol.
  • Çıkar çatışması (Conflict of Interest): The abstract does not disclose funding sources or potential conflicts of interest, which may include industry sponsorship from the device manufacturer (Ambu).
  • Genellenebilirlik (Generalizability): The study population consists exclusively of mechanically ventilated patients in the ICU. Results may not be generalisable to outpatient settings, non-ventilated patients, or those undergoing bronchoscopy for reasons other than diagnostic sampling in the ICU.
  • Istatistiksel Hassasiyet: The absence of confidence intervals and p-values makes it difficult to assess the statistical precision and significance of the observed differences, particularly the comparison of the 23.7% spill/disconnection rate against the 0% rate.
  • Verimlilik Ölçütlerinin Niteliği: Efficiency was reported qualitatively ("more efficient") rather than with quantitative metrics (e.g., mean setup time in seconds or minutes). This limits the objectivity of the efficiency comparison.

In summary, while the RASECAL trial abstract presents compelling evidence that the closed-system Ambu bronchosampler (ABS) is a safer and potentially more efficient alternative to standard sampling containers (SSC) for bronchoscopy in mechanically ventilated ICU patients, the limitations regarding data depth, study design transparency, and generalisability mean that these findings should be interpreted as preliminary. Further research using full-text publications is required to confirm these benefits and establish the device's role in clinical practice.